MXPA05006628A - Tratamiento de insuficiencia cardiaca cronica. - Google Patents

Tratamiento de insuficiencia cardiaca cronica.

Info

Publication number
MXPA05006628A
MXPA05006628A MXPA05006628A MXPA05006628A MXPA05006628A MX PA05006628 A MXPA05006628 A MX PA05006628A MX PA05006628 A MXPA05006628 A MX PA05006628A MX PA05006628 A MXPA05006628 A MX PA05006628A MX PA05006628 A MXPA05006628 A MX PA05006628A
Authority
MX
Mexico
Prior art keywords
heart failure
treatment
chronic heart
chf
heart
Prior art date
Application number
MXPA05006628A
Other languages
English (en)
Spanish (es)
Inventor
Zhao Lin
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Publication of MXPA05006628A publication Critical patent/MXPA05006628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA05006628A 2002-12-20 2003-12-11 Tratamiento de insuficiencia cardiaca cronica. MXPA05006628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/325,420 US20040122067A1 (en) 2002-12-20 2002-12-20 Treatment of chronic heart failure
PCT/US2003/039410 WO2004060489A2 (en) 2002-12-20 2003-12-11 Treatment of chronic heart failure

Publications (1)

Publication Number Publication Date
MXPA05006628A true MXPA05006628A (es) 2005-09-30

Family

ID=32593758

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006628A MXPA05006628A (es) 2002-12-20 2003-12-11 Tratamiento de insuficiencia cardiaca cronica.

Country Status (7)

Country Link
US (1) US20040122067A1 (https=)
EP (1) EP1581308A2 (https=)
JP (1) JP2006514051A (https=)
CA (1) CA2506719A1 (https=)
MX (1) MXPA05006628A (https=)
PL (1) PL375893A1 (https=)
WO (1) WO2004060489A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027887A2 (en) * 2003-09-17 2005-03-31 Cardimone Pharma Corporation Methods and compositions for improving endothelial function
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CN101646440A (zh) * 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
GB0909243D0 (en) * 2009-05-29 2009-07-15 Univ Dundee Angina treatment
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CA2955577A1 (en) 2014-07-30 2016-02-04 Teijin Pharma Limited Xanthine oxidase inhibitor
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (es) * 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
AU1520699A (en) * 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
KR100818845B1 (ko) * 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
US7417038B1 (en) * 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
EP1158989B1 (en) * 1999-03-09 2007-06-20 Anker, Stefan Use of inhibitors of endotoxin for the treatment of cachexia

Also Published As

Publication number Publication date
WO2004060489A2 (en) 2004-07-22
JP2006514051A (ja) 2006-04-27
PL375893A1 (en) 2005-12-12
EP1581308A2 (en) 2005-10-05
CA2506719A1 (en) 2004-07-22
US20040122067A1 (en) 2004-06-24
WO2004060489A3 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
MXPA05006628A (es) Tratamiento de insuficiencia cardiaca cronica.
WO2003079979A3 (en) Method for treating congestive heart failure
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
EA200500859A1 (ru) Хинолинилпирролопиразолы
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
EA200200767A1 (ru) Лечение застойной сердечной недостаточности предварительно обработанной аутологичной кровью
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
GB0223380D0 (en) Combination therapy
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
EA200200324A1 (ru) Способы применения селективных ингибиторов обратного захвата серотонина быстрого запуска для лечения половой дисфункции
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
IL169702A0 (en) Combination therapy of zd6474 with 5-fu or/and cpt-11
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
WO2005062958A3 (en) Meth0ds of using hcn genes to treat cardiac arrhythmias
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
WO2022081610A8 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
TR200003194T2 (tr) Hastalık tedavisine mahsus sPLA2 önleyici bileşikler
WO2003022882A3 (en) Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
NO20024545L (no) Fremgangsmåte for behandling av kongestiv hjertefeil
EA200400817A1 (ru) Идрапаринукс для лечения и вторичной профилактики случаев венозной тромбоэмболии у пациентов с тромбозом глубоких вен
WO2005102367A3 (en) Coadministration of radiation, efaproxiral sodium, and supplemental oxygen for the treatment of cancer
ATE472323T1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten
WO2005055923A3 (en) Method for treating athlete´s foot